Study of pucotenlimab with lenvatinib and chemo for relapsed hepatoblastoma in children
Part of Cancer clinical trials.
This trial tests a combination of an immunotherapy (pucotenlimab), a targeted therapy (lenvatinib), and chemotherapy for children with advanced or relapsed hepatoblastoma that hasn't responded to prior treatment. The goal is to see if this combination can help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be between 2 and 18 years old.
- Hepatoblastoma must be confirmed by biopsy and not have responded to at least one prior treatment, or it has come back.
- The tumor must be measurable on scans or have high alpha-fetoprotein levels.
- Child must be active enough to have a performance score of at least 50 (able to do some daily activities).
- Blood tests must show adequate organ function (e.g., proper white blood cell, platelet, and liver/kidney function).
- If child has had brain metastases, they must be treated and stable without steroids for at least 28 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the immunotherapy drug Pucotenlimab to standard chemotherapy is safe and effective for children and teens with a type of muscle cancer (rhabdomyosarcoma) that is hard to treat. It may offer a new option for patients whose tumors are difficult to remove with surgery alone.
This Phase 3 study tests a modified treatment plan for children newly diagnosed with hepatoblastoma, a type of liver cancer. It may help improve how well treatment works and how safely it can be given by using a structured approach.
This trial tests a new immunotherapy drug, pucotenlimab, for children and teens with a rare cancer called lymphoepithelioma-like carcinoma (LECC). The goal is to see if the drug is safe and helps shrink tumors.
This trial is for people with advanced head and neck cancer that has not been treated yet. It tests a combination of an immunotherapy drug (Pucotenlimab) and chemotherapy given before surgery to see if it can shrink tumors and improve outcomes.
This trial tests a combination of three treatments—a liver-directed chemotherapy infusion (HAIC), a targeted therapy pill (lenvatinib), and an immunotherapy (pucotenlimab)—to try to shrink bile duct cancers that cannot be surgically removed. The goal is to make the cancer surgically removable or to control it for as long as possible.
This trial studies pembrolizumab (an immune therapy) in children and young people with hepatocellular carcinoma (HCC) that has returned or did not respond to earlier treatment. The goal is to see whether it can shrink tumors and help control the cancer.
Hear when a new Hepatoblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.